{"classes":[{"categories":[{"measurements":[{"comment":"Upper limit not yet reached","groupId":"OG000","lowerLimit":"2.0","upperLimit":"NA","value":"36.1"},{"comment":"Upper limit not yet reached","groupId":"OG001","lowerLimit":"4.5","upperLimit":"NA","value":"7.4"},{"comment":"Upper limit not yet reached","groupId":"OG002","lowerLimit":"4.9","upperLimit":"NA","value":"15.4"},{"comment":"Upper limit not yet reached","groupId":"OG003","lowerLimit":"9.1","upperLimit":"NA","value":"23.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"11"}],"units":"Participants"}],"description":"Progression is defined using Response Evaluation Criteria in Solid Tumors criteria (RECIST v1.0) as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive carboplatin IV over 30-60 minutes on day 1 and paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG000","title":"Arm I (Carboplatin and Paclitaxel)"},{"description":"Patients receive oxaliplatin IV over 2-6 hours on day 1 and capecitabine PO BID on days 1-14. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCapecitabine: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nOxaliplatin: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG001","title":"Arm II (Oxaliplatin and Capecitabine)"},{"description":"Patients receive carboplatin and paclitaxel IV as in arm I and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive bevacizumab IV over 30-90 minutes alone on day 1. Treatment repeats every 3 weeks for 12 courses in the absence of disease progression or unacceptable toxicity.\n\nBevacizumab: Given IV\n\nCarboplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPaclitaxel: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG002","title":"Arm III (Carboplatin, Paclitaxel, Bevacizumab)"},{"description":"Patients receive oxaliplatin and capecitabine as in arm II, and bevacizumab as in arm III.\n\nBevacizumab: Given IV\n\nCapecitabine: Given PO\n\nLaboratory Biomarker Analysis: Correlative studies\n\nOxaliplatin: Given IV\n\nQuality-of-Life Assessment: Ancillary studies","id":"OG003","title":"Arm IV (Oxaliplatin, Capecitabine, Bevacizumab)"}],"paramType":"MEDIAN","populationDescription":"All Randomized Patients","reportingStatus":"POSTED","timeFrame":"Is measured from date of randomization until first indication of progression based on RECIST criteria or death from any cause, or if progression-free at last contact, the date of last disease assessment up to 10 years.","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Months"}